Tokyo, Japan

Yoshiaki Azuma

This inventor holds 5 USPTO granted patents, plus 1 CIPO patent. Top assignees: Teijin Limited, Teijin Pharma Limited. Active years: 1997-2013.


% Patents Active = 20.0


Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 38(Granted Patents)


Location History:

  • Hino, JP (1997)
  • Tokyo, JP (2005 - 2013)

Company Filing History:


Years Active: 1997-2013

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Yoshiaki Azuma: Innovator in Protein Research

Introduction

Yoshiaki Azuma is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of protein research, holding a total of 5 patents. His work focuses on developing novel polypeptides with potential therapeutic applications.

Latest Patents

One of Yoshiaki Azuma's latest patents involves a protein and its production process, aimed at providing a polypeptide with a unique structure. This polypeptide exhibits activities that inhibit angiogenesis and osteoclastogenesis. The invention also includes a method for purifying this recombinant protein, which could serve as a valuable ingredient in designing remedies for conditions such as tendinitis, rheumatoid arthritis, arthritis deformans, and malignant tumors.

Career Highlights

Throughout his career, Yoshiaki Azuma has worked with notable companies, including Teijin Limited and Teijin Pharma Limited. His experience in these organizations has contributed to his expertise in protein research and development.

Collaborations

Yoshiaki Azuma has collaborated with esteemed colleagues, including Yoshifumi Harada and Norihiro Yamada. These partnerships have further enhanced his research and innovation in the field.

Conclusion

Yoshiaki Azuma's contributions to protein research and his innovative patents highlight his role as a key figure in the scientific community. His work continues to pave the way for advancements in therapeutic solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…